Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same
AssigneesVirion Therapeutics, LLC, The Wistar Institute
InventorsHildegund CJ ERTL, Colin Stephen MAGOWAN
Life of this patent
Estimating the term…
Abstract
Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
Claims21
A nucleic acid molecule comprising a nucleotide sequence encoding a hepatitis B virus (HBV) polymerase N-terminal domain comprising the amino acid sequence of SEQ ID NO:
- 178 or an immunogenic fragment thereof.
A HBV polymerase N-terminal domain comprising the amino acid sequence of SEQ ID NO:
- 178 or an immunogenic fragment thereof.
A nucleic acid molecule comprising a nucleotide sequence encoding a HBV polymerase C-terminal domain comprising the amino acid sequence of SEQ ID NO:
- 179 or an immunogenic fragment thereof.
A HBV polymerase C-terminal domain comprising the amino acid sequence of SEQ ID NO:
- 179 or an immunogenic fragment thereof.
A nucleic acid molecule comprising a nucleotide sequence encoding a HBV Core protein comprising the amino acid sequence of SEQ ID NO:
- 180 or an immunogenic fragment thereof.
A HBV Core protein comprising the amino acid sequence of SEQ ID NO:
- 180 or an immunogenic fragment thereof.
Dependencies are inferred from the claim text.